Core Viewpoint - Corcept Therapeutics Inc. is under investigation for potentially misleading investors regarding the efficacy and commercial prospects of its drug relacorilant, following warnings from the FDA not to submit its application for approval [1][2][4]. Group 1: Company Performance and Market Impact - Corcept's shares have declined significantly, resulting in a loss of approximately $3.2 billion in market capitalization since December 2025 [2]. - The company had previously projected that its hypercortisolism business could grow from $3 billion to $5 billion in annual revenue within three to five years [3]. Group 2: Regulatory Communications and Investor Relations - On December 31, 2025, Corcept received a complete response letter (CRL) from the FDA, indicating that the agency could not reach a favorable benefit-risk assessment for relacorilant without additional evidence of effectiveness [4]. - A corrected CRL issued on January 28, 2026, revealed that the FDA had warned Corcept multiple times against submitting its application, contradicting the company's earlier statements about its communications with regulators [4]. Group 3: Legal Investigation - Hagens Berman is expanding its investigation to determine if Corcept misled investors regarding its communications with the FDA, as well as the efficacy and safety of relacorilant [5].

Core Viewpoint - Corcept Therapeutics faces significant setbacks regarding its proposed treatment for hypercortisolism, relacorilant, following warnings from the FDA not to submit its drug application, leading to a sharp decline in share price [1][2]. Company Developments - On January 30, 2026, Corcept shares dropped by $7.81, or 17%, after reports of FDA warnings against submitting the drug application [1]. - The company's market capitalization has decreased by $3.2 billion since December 30, 2025, following the receipt of a complete response letter (CRL) from the FDA [4]. FDA Communications - The FDA had previously issued a CRL indicating that it could not arrive at a favorable benefit-risk assessment for relacorilant without additional evidence of effectiveness [3]. - A corrected CRL dated January 28 revealed that the FDA had warned Corcept on multiple occasions about significant review issues if the application was submitted [3]. Investor Concerns - Hagens Berman, a law firm, is investigating whether Corcept misled investors regarding relacorilant's efficacy and the company's communications with the FDA [2][4]. - The firm is also analyzing if Corcept overstated its commercial and growth prospects for the hypercortisolism business, which was projected to grow from $3 billion to $5 billion in annual revenues within three to five years [3].

BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, announces that it is investigating potential securities law violations by Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept” or the “Company”), a company based in Redwood City, California. About the Investigation On December 31, 2025, Corcept issued a press release announcing that “U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New D ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated due to allegations of materially misleading business information issued to the investing public [1] Company Summary - Corcept Therapeutics Incorporated is facing scrutiny for potentially misleading information that may have affected its securities [1] - Shareholders who purchased Corcept securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]

NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Corcept Theraepeutics Incorporated (NASDAQ: CORT)?Did you lose money in your investment in Corcept Theraepeutics Incorporated?Do you want to discuss your rights? Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating whether Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) violated federal securities laws. If you own Corcept stock and would lik ...

Shares of Corcept Therapeutics fell 16% on Friday after a corrected "complete response letter" from the U.S. Food and Drug Administration showed the agency had warned the company "on several occasion... ...

BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Corcept Therapeutics Inc. (Nasdaq: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/cort. What is this all about? Shares of Corcept Therapeutics fell 16% in pre-market trading on January 30, after a report highlighted language in th ...

Core Viewpoint - DJS Law Group is investigating claims against Corcept Therapeutics for potential violations of securities laws following the FDA's Complete Response Letter regarding the company's New Drug Application for relacorilant, which led to a significant drop in share price [1][2]. Investigation Details - The investigation centers on whether Corcept made misleading statements or failed to disclose critical information to investors [2]. - On December 31, 2026, Corcept announced that the FDA issued a Complete Response Letter for relacorilant, despite acknowledging that the pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial provided confirmatory evidence [2]. - Following the FDA's announcement, Corcept's shares plummeted by more than 50% [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, aiming to enhance investor returns through effective advocacy [4].

Core Insights - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following a Complete Response Letter (CRL) from the FDA regarding its new drug application for relacorilant [1][2] - The FDA's decision was based on the need for additional evidence of effectiveness despite acknowledging previous trial results [2] - Following the announcement, Corcept's stock price experienced a significant drop of $31.42, equating to a 44.76% decrease, marking a new 52-week low [2][3] Company Overview - Corcept Therapeutics focuses on developing treatments for patients with conditions related to hypercortisolism, specifically hypertension [1] - The company has faced challenges in gaining FDA approval for its drug relacorilant, which has implications for its market position and investor confidence [2] Market Reaction - The stock price decline to $38.78 per share reflects investor concerns over the FDA's decision and the potential impact on the company's future [2][3] - The drop in stock price indicates a significant loss of value for shareholders, prompting investigations into the company's compliance with securities laws [1][3]

Key Takeaways CORT said the phase III ROSELLA study met its OS endpoint in platinum-resistant ovarian cancer.Data showed relacorilant plus nab-paclitaxel cut death risk 35% and lifted median OS to 16 months.Corcept said both OS and PFS endpoints were met without biomarker selection or added safety burden.Shares of Corcept Therapeutics (CORT) were up 13.7% on Jan. 22, after the company announced that the phase III ROSELLA study, which evaluated its pipeline candidate, relacorilant in combination with nab-pac ...